a single dose of Azithromycin will be administered to infants between their 8-27th days of life

a single dose of placebo will be administered to infants between their 8-27th days of life

Childhood Mortality

Azithromycin

a single dose of Placebo will be administered to infants between their 8-27th days of life

Placebo

Centre de Recherche En Santé de Nouna

Neonates and Azithromycin, an Innovation in the Treatment of Children in Burkina Faso

All-cause Mortality Rate in infants at 6 months of age

All-cause Mortality Rate in infants at 12 months of age

Caregivers will be asked if the child is dead or alive at 365 days of life

Change in weight from baseline to day 180

Change in height from baseline to day 180

Proportion of infants developing infantile hypertrophic pyloric stenosis between 2 to 8 weeks after treatment

Caregivers will be asked if their child experienced any symptoms for pyloric stenosis since the last visit.

De-identified data will be available as per the Bill and Melinda Gates open access policy. Individual participant data will be available that underline the reported results (texts, tables, figures, and appendices). The study protocol and statistical analysis plan will also be made available. The data will be available following publication in accordance with the BMGF guidelines.

University of California, San Francisco

Centre de Recherche en Sante de Nouna, Burkina Faso

Bill and Melinda Gates Foundation

individually randomized trial of azithromycin versus placebo to establish the efficacy and safety of administration of a dose of azithromycin during the neonatal period

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

pyloric stenosis/إسهال

Neonates and Azithromycin, an Innovation in the Treatment of Children in Burkina Faso

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم